Bedrijfsoverzicht
Arcutis Biotherapeutics, Inc. is a biopharmaceutical enterprise dedicated to the research, development, and commercialization of therapeutic solutions specifically targeting dermatological diseases. The company operates within the Healthcare sector, functioning more narrowly within the specialized industry of Biotechnology, which implies a focus on leveraging biological processes and products to create medicines for treating various medical conditions. As of the latest reporting period, the firm maintains a substantial market capitalization of $3.00B and generates annual revenue totaling $376.07M, supported by an operational workforce of 354 employees. These financial figures indicate that the company has achieved significant scale in a capital-intensive industry, positioning it as a notable player capable of funding extensive clinical trials and commercialization efforts for its lead products, including ZORYVE, a topical roflumilast cream designed for plaque psoriasis and atopic dermatitis.
Financiële gezondheid
The company reported a total revenue of $376.07M over the trailing twelve months, yet this generated a net income of -$16,141,000 and an EBITDA of -$7,560,000, revealing a cost structure where operating expenses significantly outpace top-line earnings, a common characteristic in the early-to-mid stages of biotechnology development. This negative free cash flow of -$15,702,750 suggests that the company is currently burning cash to fund its operations and product development, limiting its immediate financial flexibility for large-scale acquisitions or aggressive expansion without external capital injections. Despite the net loss, the company maintains robust profitability metrics at the gross level with a Gross Margin of 90.2%, indicating highly efficient production or sourcing of its key products, while an Operating Margin of 14.2% demonstrates reasonable control over general and administrative expenses relative to revenue. However, the Profit Margin stands at -4.3%, confirming that the company is currently unprofitable on a net basis, which is typical for firms investing heavily in R&D before achieving breakeven. The balance sheet shows a cash position of $220.98M against total debt of $114.52M, resulting in a Debt to Equity ratio of 60.44, which presents a leveraged profile where liabilities exceed equity but are partially offset by significant cash reserves. Liquidity is further supported by a Current Ratio of 3.17, indicating that the company holds more than three times the assets necessary to cover its short-term liabilities, suggesting a comfortable buffer against immediate financial obligations. Return on Equity is recorded at -9.3% and Return on Assets at -2.0%, metrics that collectively reveal that management is currently utilizing shareholder capital and company assets to generate losses rather than profits, reflecting the strategic investment phase of the business model.
Waarderingsbeoordeling
Valuation metrics for Arcutis Biotherapeutics show a trailing P/E ratio that is N/A due to the lack of recent earnings, while the Forward P/E is listed at 18.94, implying that the market prices the stock based on anticipated future profitability rather than current historical performance. The Price to Book ratio stands at 15.76, indicating that the market values the company at a significant premium over its net asset book value, which often reflects the high intangible value of intellectual property and pipeline potential in the biotech sector. Additionally, the Price to Sales ratio is 7.98 and the EV/EBITDA is -383.12, suggesting that traditional earnings-based valuation models are less applicable and that investors are relying on revenue multiples and forward-looking earnings expectations to assess value. The stock has experienced considerable volatility, trading between a 52-week low of $12.42 and a 52-week high of $31.77, placing the current market price within a wide historical range that reflects ongoing market sentiment regarding the company's clinical progress. The Beta value of 1.77 indicates that the stock's price volatility is substantially higher than that of the broader market, meaning the share price tends to fluctuate more aggressively than the general market index during periods of instability.
Growth & Income
Revenue growth is reported at an impressive 81.5% year-over-year, while earnings growth is N/A, indicating that the company is prioritizing rapid top-line expansion over immediate profitability, a strategy often seen in growth-oriented biotechnology firms. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, as evidenced by the 0.0% figure, which signifies that all available earnings and cash flows are being reinvested directly into research, development, and commercial activities to fuel future growth. The absence of a dividend policy combined with negative net income confirms that the firm is in a stage where capital allocation is focused entirely on sustaining operations and advancing its dermatological disease treatments rather than returning value to shareholders. Overall, the company's profile is defined by rapid revenue expansion and a reinvestment-heavy approach, characteristic of a biopharmaceutical entity scaling its commercial footprint to capture market share for its specialized dermatological therapies.